EGFR基因突变类型及状态与晚期非小细胞肺癌化疗疗效的相关性  

Association between epidermal growth factor receptor mutation and chemotherapeutic efficacy in advanced non-small cell lung cancer patients

作　　者：田保国[1] 史艳春[1] 孙婷[1] 王艳[1] 荆结线[1] Tian Baoguo;Shi Yanchun;Sun Ting;Wang Yan;Jing Jiexian(Department of Etiology,Shanxi Cancer Hospital,Taiyuan 030013,China)

机构地区：[1]山西省肿瘤医院病因室,太原030013

出　　处：《中国医师杂志》2020年第4期521-524,共4页Journal of Chinese Physician

摘　　要：目的探索表皮生长因子受体(EGFR)基因突变状态与晚期非小细胞肺癌化疗疗效之间的相关性。方法回顾性纳入就诊于本院的490例晚期非小细胞肺癌患者并收集相关临床病理资料,通过Kaplan-Meire法绘制生存曲线,进行Log-rank检验,并通过Cox比例风险模型进行多因素校正。结果490例患者中,202(41.2%)例存在EGFR基因突变,EGFR突变的患者接受化疗后,其疾病控制率高于野生组患者,但差异无统计学意义(72.8%vs 66.0%,P=0.11)。突变阳性组与突变阴性组的无进展生存时间(PFS)分别为6.00个月和6.13个月,差异无统计学意义(P=0.55)。携带有19del及21L858R突变患者的PFS分别为5.97个月和6.23个月,差异无统计学意义(P=0.79)。结论EGFR突变状态及突变类型不是晚期非小细胞肺癌一线化疗的疗效预测标志物。Objective The aim of the study was to investigate the association between epidermal growth factor receptor(EGFR)mutation and chemotherapeutic efficacy in advanced non-small cell lung cancer(NSCLC)patients.Methods A total number of 490 patients with advanced non-small cell lung cancer were investigated in this retrospective study.Clinical outcomes were analyzed according to EGFR mutation status and mutation type based on Kaplan-Meier method and Cox regression model.Results EGFR mutation was detected in 202(41.2%)NSCLC patients.There was a trend that EGFR mutant patients had a higher response rate compared with wild type NSCLC patients,with non statistical significance(72.8%versus 66.0%,P=0.11).No difference was observed in progression free survival of first-line chemotherapy between EGFR negative and positive patients(6.00 versus 6.13 months,P=0.55).Patients harboring exon 19 deletion and exon 21 L858R point mutation derived similar progression free survival(PFS)(5.97 versus 6.23 months,P=0.79).Conclusions EGFR mutation status and mutation type are not prognostic factors to first-line platinum-based chemotherapy in advanced NSCLC.

关 键 词：受体 表皮生长因子 突变 癌 非小细胞肺 抗肿瘤联合化疗方案 

分 类 号：R734.2[医药卫生—肿瘤]